VAKCINA

Pfizer CEO Bourla says vaccine adapted to Omicron will be ready in March https://t.co/rI2yU2I7Pu

— Gabriel Hébert-Mild ⓥ (@Gab_H_R) January 10, 2022

U.K. government advisers have recommended against giving a fourth dose of COVID-19 vaccine to nursing home residents and people over 80 because data shows that a third shot offers lasting protection against admission to the hospital.
For people over 65, protection against hospitalization remains at about 90% three months after the third dose, according to data compiled by the U.K. Health Security Agency.
As a result, the Joint Committee on Vaccination and Immunization on Friday advised the government that there was no need to offer a fourth dose, or second booster, to vulnerable people at this time. Instead, the government should focus on giving a third dose to as many people as possible to boost protection against the highly transmissible omicron variant.
“The current data show the booster dose is continuing to provide high levels of protection against severe disease, even for the most vulnerable older age groups,’’ said Prof. Wei Shen Lim, the committee’s chair. “For this reason, the committee has concluded there is no immediate need to introduce a second booster dose, though this will continue to be reviewed.’’

Repeated Covid Boosters Not A Viable Strategy: WHO
By AFP - Agence France Presse
January 11, 2022


WHO experts warned Tuesday that repeating booster doses of the original Covid vaccines is not a viable strategy against emerging variants and called for new jabs that better protect against transmission.

An expert group created by the World Health Organization to assess the performance of Covid-19 vaccines said simply providing fresh jabs of existing Covid vaccines as new strains of the virus emerge was not the best way to fight the pandemic.

"A vaccination strategy based on repeated booster doses of the original vaccine composition is unlikely to be appropriate or sustainable," the WHO Technical Advisory Group on Covid-19 Vaccine Composition (TAG-Co-VAC) said in a statement.

It said preliminary data indicated the existing vaccines were less effective at preventing symptomatic Covid disease in people who have contracted the new Omicron variant, currently spreading like wildfire around the world.

But protection against severe disease, which is what the jabs were especially intended to do, "is more likely to be preserved".

It recommended developing vaccines that not only protect people against falling seriously ill but could also better prevent infection and transmission in the first place.

"Covid-19 vaccines that have high impact on prevention of infection and transmission, in addition to the prevention of severe disease and death, are needed and should be developed," TAG-Co-VAC said.

"Until such vaccines are available, and as the SARS-CoV-2 virus evolves, the composition of current Covid-19 vaccines may need to be updated, to ensure that (they) continue to provide WHO-recommended levels of protection against infection and disease by VOCs (variants of concern), including Omicron and future variants."

European Union regulators warned that frequent Covid-19 booster shots could adversely affect the immune response and may not be feasible.

Repeat booster doses every four months could eventually weaken the immune response and tire out people, according to the European Medicines Agency. Instead, countries should leave more time between booster programs and tie them to the onset of the cold season in each hemisphere, following the blueprint set out by influenza vaccination strategies, the agency said.

Pfizer CEO Albert Bourla on Monday said a vaccine that targets the omicron variant of Covid will be ready in March, and the company’s already begun manufacturing the doses.
“This vaccine will be ready in March,” Bourla told CNBC’s “Squawk Box.” “We [are] already starting manufacturing some of these quantities at risk.”
Bourla said the vaccine will also target the other variants that are circulating. He said it is still not clear whether or not an omicron vaccine is needed or how it would be used, but Pfizer will have some doses ready since some countries want it ready as soon as possible.
“The hope is that we will achieve something that will have way, way better protection particularly against infections, because the protection against the hospitalizations and the severe disease — it is reasonable right now, with the current vaccines as long as you are having let’s say the third dose,” Bourla said.

The European Commission has granted conditional marketing authorisation for US biotech firm Novavax’s COVID-19 vaccine, Nuvaxovid, on Monday (20 December) following the European Medicines Agency (EMA) recommendation.

Nuvaxovid is the fifth vaccine authorised in the EU for preventing COVID-19 after those developed by BioNTech and Pfizer, Moderna, AstraZeneca, and Janssen Pharmaceutica NV.

The President of the European Commission, Ursula von der Leyen, tweeted: “With 5 approved vaccines, the EU has a varied portfolio, based both on novel technologies, such as mRNA, and classic ones, like Novavax, which is protein-based”.

Results from two main clinical trials are promising for Novavax’s vaccine when fighting the original strain of SARS-CoV-2 and some variants of concern such as Alpha and Beta. Rates of 90% efficiency at preventing COVID-19 in people over 18 years of age were found in both studies.

But with the new variants, such as Omicron, its efficiency is unknown. The EMA’s press release states that “there is currently limited data on the efficacy of Nuvaxovid against other variants of concern, including Omicron”.

Nuvaxovid is given as two injections, three weeks apart. Side effects reported in the studies were usually mild or moderate and cleared within a couple of days. Tenderness or pain at the injection site, tiredness, and muscle pain were among those most commonly reported.

Mađarska će ponuditi četvrtu dozu vakcine protiv koronavirusa svom stanovništvu u pokušaju da zaustavi nagli porast broja zaraženih tim virusom. I Španija je odobrila četvrtu dozu vakcine za najosetljivije grupe sa ugroženim imunitetom.

ficfiric wrote:Sad ne kuzim cemu cetvrta doza ako omikron probija vakcinu?

lalinea wrote:

ficfiric wrote:Sad ne kuzim cemu cetvrta doza ako omikron probija vakcinu?

zato sto u prvim nedeljama nakon bustera efektivnost vakcine protiv omikrona skace i to nesto puno. pa valjda tom logikom, ajde opet da bustujemo. ali nema podataka uopste o toj 4. dozi, sta radi, d ali je to dobra strategija, i meni je ta zurba sa 4. dozom bzvz.

Expert at Sheba Medical Center says jab raises COVID antibody levels, but there are ‘still a lot of infections’ among those who received it

Sotir wrote:Ово срање од омикрона је толико заразно да док смисле стратегију или адекватну вакцину проћи ће воз. 

Да се овако нешто појавило док није било имунитета настао би помор свуда.

Mór Thököly wrote:

Sotir wrote:Ово срање од омикрона је толико заразно да док смисле стратегију или адекватну вакцину проћи ће воз. 

Да се овако нешто појавило док није било имунитета настао би помор свуда.

to bi bio pakao. ne bismo znali sta nas je snaslo, vec bi bio smak sveta